IPSEY News and Press, Ipsen SA ADR From 04/05/24

2024-04-05 18:31:56 ET Summary Ipsen S.A. is a pharmaceutical company focused on oncology, rare disease, and neuroscience, with a portfolio of commercial drug products. The company generated $3.4bn in revenues in 2023, with a core consolidated net profit of $830m. Ipsen typica...

Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...

2024-04-02 04:03:00 ET Ipsen ( OTCPK:IPSEY ) has secured exclusive global rights for the development and commercialization of STRO-003, an antibody-drug conjugate, from Sutro Biopharma ( NASDAQ: STRO ), completing the final stages of pre-clinical development, the compa...

2024-03-25 13:07:32 ET Summary M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot ...

2024-02-13 16:38:09 ET More on Ipsen S.A. Ipsen S.A. Non-GAAP EPS of €9.15, revenue of €3.13B; initiates FY24 outlook FDA grants priority review of Genfit-Ipsen liver disease drug Historical earnings data for Ipsen S.A. Dividend scorecard for Ip...

2024-02-13 13:35:30 ET More on Merrimack Financial information for Merrimack Pharmaceuticals Read the full article on Seeking Alpha For further details see: Merrimack spikes as Ipsen wins FDA label expansion for cancer therapy

2024-02-09 15:00:09 ET More on the markets SPY: Larger Treasury Issuances And Fewer Fed Cuts Are Not Priced In My Current View Of The S&P 500 Index: February 2024 Edition (Technical Analysis) 2024 Analyst Outlook: Yiannis Zourmpanos On Cautious Optimism For The N...

Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...

2024-02-08 01:14:21 ET More on Ipsen: FDA grants priority review of Genfit-Ipsen liver disease drug Genfit stock rallies 20% after hours on data for liver disease drug Historical earnings data for Ipsen S.A. Dividend scorecard for Ipsen S.A. Financial...

2023-12-19 09:10:24 ET Summary Mirum Pharmaceuticals, Inc. stock dropped 16% after its lead asset, Livmarli, failed to meet primary or secondary endpoints in a phase 2 trial for biliary atresia. This looks like an overreaction considering the small addressable market and no negati...